The Latest Breaking News from AstraZeneca

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

Speaking publicly for the first time, her family say they fully support the COVID-19 vaccine rollout, but believe the government should have had a better plan to support families like theirs.

The renowned immunologist remains as upbeat about jabs – and UK life science – as he was in the depths of the pandemic

Here's a roundup of top developments in the biotech space over the last 24 hours:

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

More than 1,200 claims have been made to the government’s Vaccines Damages Payment Scheme, but no compensation has yet to be paid out

 Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.

Pharmaceutical CEO says it’s ‘sad’ that UK has failed to order Evusheld for the immunosuppressed